New quality of life data with immune-based treatment of metastatic renal cell carcinoma
Even in a first-line setting, where patient’s aims are usually unbalanced towards better antitumor activity and efficacy, QoL remains an important endpoint to pursue. In this MEDtalk Camilo Porta, Italy, presents new Quality of Life data from ESMO 2021.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in